JP2016539146A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539146A5 JP2016539146A5 JP2016536232A JP2016536232A JP2016539146A5 JP 2016539146 A5 JP2016539146 A5 JP 2016539146A5 JP 2016536232 A JP2016536232 A JP 2016536232A JP 2016536232 A JP2016536232 A JP 2016536232A JP 2016539146 A5 JP2016539146 A5 JP 2016539146A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- phenyl
- pyridin
- alkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 azetidine-1,3-diyl Chemical group 0.000 claims 437
- 125000000217 alkyl group Chemical group 0.000 claims 96
- 229910052739 hydrogen Inorganic materials 0.000 claims 64
- 239000001257 hydrogen Substances 0.000 claims 64
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 32
- 150000002431 hydrogen Chemical group 0.000 claims 32
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 7
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 6
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 6
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 5
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 5
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 4
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 4
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 4
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 4
- 102000015303 Fatty Acid Synthases Human genes 0.000 claims 4
- 108010039731 Fatty Acid Synthases Proteins 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims 4
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 4
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 3
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 3
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 3
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 3
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 3
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 3
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 claims 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- ZWRZCDONABWGJD-UHFFFAOYSA-N N-[2-methyl-5-[3-[4-(1-methylpyrazol-4-yl)phenyl]azetidine-1-carbonyl]phenyl]-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC1=C(C=C(C=C1)C(=O)N1CC(C1)C1=CC=C(C=C1)C=1C=NN(C1)C)NC(C1=CN=C(C=C1)N1CCOCC1)=O ZWRZCDONABWGJD-UHFFFAOYSA-N 0.000 claims 2
- RQFMIPGIMUVBFA-UHFFFAOYSA-N N-[2-methyl-5-[4-[4-(1-methylpyrazol-4-yl)phenyl]piperidine-1-carbonyl]phenyl]-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC1=C(C=C(C=C1)C(=O)N1CCC(CC1)C1=CC=C(C=C1)C=1C=NN(C1)C)NC(C1=CN=C(C=C1)N1CCOCC1)=O RQFMIPGIMUVBFA-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- OJGDKDGMYFJGFE-UHFFFAOYSA-N n-[2-ethyl-5-[4-[4-(1-methylpyrazol-4-yl)phenyl]piperidine-1-carbonyl]phenyl]-6-(propan-2-ylamino)pyridine-3-carboxamide Chemical compound CCC1=CC=C(C(=O)N2CCC(CC2)C=2C=CC(=CC=2)C2=CN(C)N=C2)C=C1NC(=O)C1=CC=C(NC(C)C)N=C1 OJGDKDGMYFJGFE-UHFFFAOYSA-N 0.000 claims 2
- UINDVWPUJUATBB-UHFFFAOYSA-N n-[2-methyl-5-[4-[4-(1-methylpyrazol-4-yl)phenyl]piperidine-1-carbonyl]phenyl]-6-(propan-2-ylamino)pyridine-3-carboxamide Chemical compound C1=NC(NC(C)C)=CC=C1C(=O)NC1=CC(C(=O)N2CCC(CC2)C=2C=CC(=CC=2)C2=CN(C)N=C2)=CC=C1C UINDVWPUJUATBB-UHFFFAOYSA-N 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 2
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 claims 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- LZNHLUZIPBTPEW-UHFFFAOYSA-N N-[2-(methylamino)-5-[4-[4-(1-methylpyrazol-4-yl)phenyl]piperidine-1-carbonyl]phenyl]-6-(propan-2-ylamino)pyridine-3-carboxamide Chemical compound C(C)(C)NC1=NC=C(C(=O)NC2=C(C=CC(=C2)C(=O)N2CCC(CC2)C2=CC=C(C=C2)C=2C=NN(C2)C)NC)C=C1 LZNHLUZIPBTPEW-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000021017 Weight Gain Diseases 0.000 claims 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000006311 cyclobutyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 235000020825 overweight Nutrition 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011096 spinal cancer Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000014618 spinal cord cancer Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 0 Cc1ccc(*)c(*)c1 Chemical compound Cc1ccc(*)c(*)c1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361911016P | 2013-12-03 | 2013-12-03 | |
| US61/911,016 | 2013-12-03 | ||
| PCT/US2014/066743 WO2015084606A1 (en) | 2013-12-03 | 2014-11-21 | Benzamide derivative useful as fasn inhibitors for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539146A JP2016539146A (ja) | 2016-12-15 |
| JP2016539146A5 true JP2016539146A5 (enExample) | 2019-03-07 |
| JP6611358B2 JP6611358B2 (ja) | 2019-11-27 |
Family
ID=52146686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536232A Expired - Fee Related JP6611358B2 (ja) | 2013-12-03 | 2014-11-21 | 癌治療のためのｆａｓｎ阻害剤として有用なベンズアミド誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9562035B2 (enExample) |
| EP (1) | EP3077387B1 (enExample) |
| JP (1) | JP6611358B2 (enExample) |
| CA (1) | CA2932396C (enExample) |
| WO (1) | WO2015084606A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11202795B2 (en) | 2014-11-20 | 2021-12-21 | Vib Vzw | Means and methods for treatment of early-onset Parkinson's disease |
| EP3310773B1 (en) | 2015-06-18 | 2020-12-02 | 89Bio Ltd. | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
| CN107847765B (zh) | 2015-06-18 | 2021-05-04 | 89生物有限公司 | 1,4-取代的哌啶衍生物 |
| CN105175284B (zh) * | 2015-07-21 | 2017-06-16 | 中国药科大学 | 酰胺类化合物、制备方法及其医药用途 |
| DK3458448T3 (da) * | 2016-04-25 | 2021-08-23 | Forma Therapeutics Inc | Fasn-inhibitorer til anvendelse til behandling af non-alkoholisk steatohepatitis |
| CA3043308A1 (en) * | 2016-11-11 | 2018-05-17 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
| EP3636637A1 (en) * | 2018-10-10 | 2020-04-15 | Forma Therapeutics, Inc. | Inhibiting fatty acid synthase (fasn) |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| CN109369634B (zh) * | 2018-12-19 | 2021-07-27 | 陕西国际商贸学院 | 具有抗肿瘤活性的2-甲氧基烟酰胺衍生物制备方法及用途 |
| CN111777593B (zh) * | 2019-04-03 | 2024-07-23 | 南京天印健华医药科技有限公司 | 作为转染期间重排激酶抑制剂的新的化合物 |
| EP4096661B1 (en) * | 2020-01-29 | 2025-04-02 | Kamari Pharma Ltd. | Compounds and compositions for use in treating skin disorders |
| WO2022087422A1 (en) * | 2020-10-22 | 2022-04-28 | Chulalongkorn University | Pyrrolidine-3-carboxamide derivatives and related uses |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008059214A1 (en) * | 2006-11-13 | 2008-05-22 | Astrazeneca Ab | Bisamlde derivatives and use thereof as fatty acid synthase inhibitors |
| TW200833663A (en) * | 2006-12-21 | 2008-08-16 | Astrazeneca Ab | Therapeutic agents |
| TW200831092A (en) * | 2006-12-21 | 2008-08-01 | Astrazeneca Ab | Therapeutic agents |
-
2014
- 2014-11-21 WO PCT/US2014/066743 patent/WO2015084606A1/en not_active Ceased
- 2014-11-21 EP EP14819146.3A patent/EP3077387B1/en active Active
- 2014-11-21 CA CA2932396A patent/CA2932396C/en active Active
- 2014-11-21 US US14/550,349 patent/US9562035B2/en not_active Expired - Fee Related
- 2014-11-21 JP JP2016536232A patent/JP6611358B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539146A5 (enExample) | ||
| JP6884102B2 (ja) | がんの治療のための化合物 | |
| CN101641093B (zh) | 作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶 | |
| CA2351725A1 (en) | Substituted pyrazoles as p38 kinase inhibitors | |
| CN102056927B (zh) | 作为激酶抑制剂的稠合含氮杂环及其组合物 | |
| CN106132950B (zh) | 氨基吡啶类化合物和使用方法 | |
| TWI690525B (zh) | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 | |
| RU2507204C2 (ru) | Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона | |
| RU2019118623A (ru) | Пирролопиримидины в качестве потенциаторов мвтр | |
| JP2013528591A5 (enExample) | ||
| JP2007504148A5 (enExample) | ||
| JP2011509937A5 (enExample) | ||
| KR20160104036A (ko) | 세린/트레오닌 키나제 저해제 | |
| CA2531619A1 (en) | Biaryl piperazinyl-pyridine analogues | |
| EA030376B1 (ru) | Азетидиновые производные пиперидин-4-ила как ингибиторы jak1 | |
| JP2013545808A (ja) | ＩＩＩ型受容体チロシンキナーゼ阻害剤としての置換Ｎ−（１Ｈ−インダゾール−４−イル）イミダゾ［１，２−ａ］ピリジン−３−カルボキサミド化合物 | |
| WO2012085815A1 (en) | Bi-heteroaryl compounds as vps34 inhibitors | |
| JP2016522231A5 (enExample) | ||
| CN104583197A (zh) | 新型双环吡啶衍生物 | |
| JP2016514717A5 (enExample) | ||
| JP2016523976A5 (enExample) | ||
| JP2010523677A (ja) | 癌の治療のためのＰＩ３Ｋα阻害剤としてのピリド［２，３−Ｄ］ピリミジン−７−オン | |
| JP2019505594A5 (enExample) | ||
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
| WO2014106800A2 (en) | Substituted 2-amino pyrimidine derivatives as kinase inhibitors |